Atypical Pneumonia (Mycoplasma pneumoniae)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Atypical Pneumonia (Mycoplasma pneumoniae) is a type of lung infection that affects the respiratory system, particularly the lungs. It is caused by a small bacterium called Mycoplasma pneumoniae that lacks a cell wall, making it different from typical bacteria. This infection often leads to symptoms like a persistent dry cough, mild fever, and fatigue, which can last for several weeks. Unlike typical pneumonia, it usually causes less severe symptoms but can still significantly impact breathing and daily activities. The illness spreads through respiratory droplets when an infected person coughs or sneezes. It mainly affects children and young adults but can occur at any age. Early recognition of symptoms is important for diagnosis and management.

Clinical Definition

Mycoplasma pneumoniae pneumonia is community-acquired lung infection caused by a bacterium without a cell wall, making beta-lactams ineffective against it. Adhesion to respiratory epithelium, toxin effects and host inflammation impair mucociliary function. Gradual cough, fever and malaise are typical, but severity and imaging vary; patchy bronchopneumonia or consolidation can occur. Hemolysis, neurologic disease and severe mucositis are recognized but uncommon complications.

Inciting Event

  • Inhalation of respiratory droplets containing Mycoplasma pneumoniae initiates infection.

  • Exposure to an infected individual during close prolonged contact triggers disease onset.

Latency Period

  • Symptoms typically develop after an incubation period of 1 to 4 weeks following exposure.

  • The gradual onset reflects the slow replication and immune response to the organism.

Diagnostic Delay

  • Initial symptoms are often nonspecific and mild, leading to misdiagnosis as viral upper respiratory infection.

  • Symptoms overlap with other infections and testing may not be ordered. Rapid respiratory molecular assays are available and are preferred when etiologic confirmation is needed.

  • Chest X-rays may show nonspecific interstitial infiltrates, which can be mistaken for other pneumonias.

Clinical Presentation


Signs & Symptoms

  • Gradual onset of dry cough and low-grade fever

  • Headache and malaise are common systemic symptoms

  • Sore throat and hoarseness may precede cough

  • Extrapulmonary manifestations include rash, hemolytic anemia, and neurologic symptoms

  • Chest discomfort can occur; pleuritic pain or marked respiratory distress should prompt assessment for severe disease, an effusion or another diagnosis rather than excluding Mycoplasma.

History of Present Illness

  • Gradual onset of dry cough, low-grade fever, and malaise over several days to weeks.

  • Associated symptoms include headache, sore throat, and myalgias.

  • Cough often becomes persistent and may be accompanied by wheezing or dyspnea.

  • Extrapulmonary symptoms such as rash or hemolytic anemia may develop later.

Past Medical History

  • History of recent upper respiratory tract infection may precede pneumonia symptoms.

  • Previous episodes of atypical pneumonia increase suspicion for recurrence.

  • Underlying chronic lung disease can worsen clinical course.

Family History

  • No significant familial genetic predisposition is associated with Mycoplasma pneumoniae infection.

  • Clusters of cases may occur in families due to shared environmental exposure.

Physical Exam Findings

  • Fever with generally mild respiratory distress

  • Scattered or localized crackles/rhonchi and wheezing may occur; focal consolidation is possible and examination can underestimate radiographic disease.

  • Pharyngeal erythema without exudate

  • Non-exudative conjunctivitis may be present

  • Assess respiratory rate, oxygenation and work of breathing to judge severity; relative bradycardia is not a reliable Mycoplasma-specific sign.

Diagnostic Workup


Diagnostic Criteria

Establish a compatible pneumonia syndrome and assess severity. No clinical or radiographic pattern alone proves Mycoplasma infection. When organism testing is indicated, respiratory NAAT/PCR is preferred and must be interpreted with the clinical picture. Serology has timing and specificity limitations; a single positive IgM is not definitive. Culture is slow and specialized. Cold agglutinins are nonspecific, and coinfection is possible.

Pathophysiology


Key Mechanisms

  • Adherence of Mycoplasma pneumoniae to respiratory epithelial cells via P1 adhesin causes ciliary dysfunction and epithelial injury.

  • Immune-mediated inflammation triggered by host response leads to interstitial pneumonia and systemic symptoms.

  • Oxidant injury and CARDS toxin, an ADP-ribosylating/vacuolating toxin, contribute to epithelial damage alongside the host inflammatory response.

  • Cold-antibody hemolysis is IgM/complement-mediated (type II), not type IV delayed hypersensitivity. Other extrapulmonary manifestations can involve different direct or immune mechanisms.

InvolvementDetails
Organs

Lungs are the primary organs affected, with inflammation of the alveoli and interstitium causing atypical pneumonia symptoms.

Upper respiratory tract involvement may cause pharyngitis and tracheobronchitis as part of the clinical presentation.

Tissues

Respiratory epithelium is damaged by Mycoplasma pneumoniae adherence and immune-mediated injury, leading to impaired mucociliary clearance.

Alveolar tissue undergoes inflammation and edema, contributing to impaired gas exchange in atypical pneumonia.

Cells

Alveolar macrophages play a key role in phagocytosing Mycoplasma pneumoniae and initiating the immune response.

Neutrophils contribute to lung inflammation and tissue damage during the immune response to infection.

Epithelial cells of the respiratory tract are the primary site of Mycoplasma pneumoniae attachment and colonization.

Chemical Mediators

Interleukin-8 (IL-8) recruits neutrophils to the site of infection, amplifying lung inflammation.

Tumor necrosis factor-alpha (TNF-α) mediates systemic symptoms such as fever and malaise in atypical pneumonia.

IgM cold agglutinins, classically directed against the erythrocyte I antigen, can activate complement and cause hemolysis; most infections do not produce clinically important anemia.

Treatments


Pharmacological Treatments

  • Macrolides (e.g., azithromycin)

    • Mechanism:
      • Inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit of Mycoplasma pneumoniae.

    • Side effects:
      • Gastrointestinal upset

      • QT prolongation

      • Hepatotoxicity

    • Clinical role:
      • Common treatment option for Mycoplasma pneumonia in children and adults. Consider macrolide resistance and reassess nonresponse.

  • Tetracyclines (e.g., doxycycline)

    • Mechanism:
      • Inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit, effective against Mycoplasma pneumoniae.

    • Side effects:
      • Photosensitivity

      • Tetracycline-class tooth/bone cautions during development; brief doxycycline courses have a substantially lower demonstrated dental risk than older tetracyclines

      • Gastrointestinal upset and pill esophagitis

    • Clinical role:
      • Doxycycline is an option for adults and appropriate older children, including macrolide nonresponse; use in younger children or pregnancy requires indication-specific benefit-risk assessment.

  • Fluoroquinolones (e.g., levofloxacin)

    • Mechanism:
      • Inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in Mycoplasma pneumoniae.

    • Side effects:
      • Tendonitis and tendon rupture

      • QT prolongation

      • Peripheral neuropathy and CNS effects; may worsen myasthenia gravis

    • Clinical role:
      • Respiratory fluoroquinolone option in adults when clinically appropriate; balance serious adverse effects and alternatives. Not routine pediatric first-line therapy.

Non-pharmacological Treatments

  • Supportive care including adequate hydration and rest to aid recovery from atypical pneumonia.

  • Oxygen therapy for patients with hypoxemia to maintain adequate tissue oxygenation.

  • Monitor breathing and hydration; fever/pain medicines such as acetaminophen are pharmacologic supportive treatment rather than a nonpharmacological intervention.

Prevention


Pharmacological Prevention

  • No vaccine is available. Antibiotics treat clinically indicated Mycoplasma pneumonia; treatment should not be presented as proven routine transmission prophylaxis.

  • Do not routinely prescribe azithromycin to exposed contacts; institutional outbreak decisions require public-health or infectious-disease guidance.

  • No routine chemoprophylaxis recommended for general population

Non-pharmacological Prevention

  • Hand hygiene to reduce respiratory droplet spread

  • Avoidance of close contact with infected individuals during outbreaks

  • Respiratory etiquette including covering coughs and sneezes

  • Use standard plus droplet precautions for Mycoplasma pneumonia in healthcare for the duration of illness; follow local guidance for communal-setting outbreaks.

Outcome & Complications


Complications

  • Secondary cold agglutinin syndrome can cause hemolytic anemia through IgM/complement-mediated red-cell injury; this postinfectious process differs from chronic clonal cold agglutinin disease.

  • Reactive infectious mucocutaneous eruption (RIME) can cause severe oral, ocular or genital mucositis with variable skin lesions. Mycoplasma-associated cases are often called MIRM; distinguish this from drug-associated SJS/TEN.

  • Guillain-Barré syndrome as a post-infectious neurologic complication

  • Secondary bacterial pneumonia from superinfection

Short-term Sequelae Long-term Sequelae
  • Persistent cough lasting weeks after acute illness

  • Fatigue and malaise during convalescence

  • Transient arthralgias or rash

  • Hypoxemia varies in severity; severe pneumonia can require hospitalization and respiratory support despite the usual mild course.

  • Rare development of bronchiectasis after severe or recurrent infections

  • Chronic cough due to airway hyperreactivity

  • Possible reactive airway disease exacerbation

  • No significant long-term pulmonary fibrosis typically

Differential Diagnoses


Atypical Pneumonia (Mycoplasma pneumoniae) versus Streptococcus pneumoniae pneumonia

Atypical Pneumonia (Mycoplasma pneumoniae)

Streptococcus pneumoniae pneumonia

Patchy bronchopneumonia, interstitial change or consolidation; no unique X-ray pattern.

Lobar consolidation is classic but not universal; imaging alone does not identify pneumococcus.

No cell wall; not visible on Gram stain

Encapsulated Gram-positive diplococci may be seen in an adequate sputum specimen; a negative Gram stain does not exclude infection.

Gradual onset with dry cough and low-grade fever

Classically abrupt fever and productive cough, but presentations overlap with atypical pathogens.

Atypical Pneumonia (Mycoplasma pneumoniae) versus Chlamydophila pneumoniae pneumonia

Atypical Pneumonia (Mycoplasma pneumoniae)

Chlamydophila pneumoniae pneumonia

Cell-wall-lacking bacterium; respiratory NAAT is the preferred diagnostic method.

Obligate intracellular bacterium; respiratory NAAT is preferred for acute infection.

Mild respiratory symptoms with extrapulmonary manifestations

Mild respiratory symptoms with prolonged cough

Compatible illness with respiratory NAAT detection; isolated seropositivity is insufficient.

Respiratory NAAT supports acute C. pneumoniae infection; a single positive IgG titer does not establish it.

Atypical Pneumonia (Mycoplasma pneumoniae) versus Legionella pneumophila pneumonia

Atypical Pneumonia (Mycoplasma pneumoniae)

Legionella pneumophila pneumonia

Usually close person-to-person respiratory exposure.

Exposure to contaminated aerosolized water, including cooling towers or building plumbing; ordinary home/car air conditioning is not the same exposure.

No required sodium or liver-enzyme pattern; normal values are not diagnostic.

Hyponatremia or elevated aminotransferases can support suspicion but are nonspecific and may be absent.

No routine Mycoplasma urine-antigen test; use respiratory NAAT when indicated.

Urine antigen usually detects only L. pneumophila serogroup 1. Pair with lower-respiratory NAAT/culture; a negative urine test does not exclude Legionella.

Atypical Pneumonia (Mycoplasma pneumoniae) versus Viral pneumonia (e.g., Influenza virus)

Atypical Pneumonia (Mycoplasma pneumoniae)

Viral pneumonia (e.g., Influenza virus)

Often gradual cough with fever, headache and malaise.

Influenza often begins abruptly with systemic symptoms, but other viral pneumonias and coinfections can resemble Mycoplasma.

Variable patchy or diffuse infiltrates, sometimes consolidation.

Variable interstitial or air-space opacities; substantial imaging overlap prevents reliable etiologic distinction.

Mycoplasma NAAT may support the diagnosis; a viral coinfection can still be present.

Viral NAAT supports viral infection. Negative rapid antigen tests do not reliably exclude influenza, and a positive viral test does not exclude bacterial coinfection.

Atypical Pneumonia (Mycoplasma pneumoniae) versus Tuberculosis

Atypical Pneumonia (Mycoplasma pneumoniae)

Tuberculosis

Often subacute respiratory illness; prolonged cough alone does not distinguish it from TB.

Chronic symptoms with weight loss, night sweats, and hemoptysis

Usually noncavitary patchy infiltrates; cavitation warrants assessment for another cause or complication.

Upper-lobe cavitation suggests reactivation TB, but TB can be noncavitary or have other patterns, particularly in children or immunocompromised patients.

Respiratory Mycoplasma NAAT with compatible illness; negative AFB smear is not a diagnostic criterion.

Evaluate with M. tuberculosis NAAT and mycobacterial culture plus AFB smears. A positive smear is not species-specific, and a negative smear does not exclude TB.